Endothelial nitric oxide synthase gene intron 4 VNTR polymorphism in sickle cell disease: Relation to vasculopathy and disease severity

Pediatric Blood and Cancer

Volumn 62, Issue 3, 2015, Pages 389-394

  Tantawy, Azza Abdel Gawad ^a   Adly, Amira Abdel Moneam ^a   Ismail, Eman Abdel Rahman ^a   Aly, Shereen Hussiny ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Endothelial dysfunction; Nitric oxide synthase gene polymorphism; SCD

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; NITRIC OXIDE; FERRITIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; HYDROLYASE; LACTATE DEHYDRATASE; NOS3 PROTEIN, HUMAN; VON WILLEBRAND ANTIGEN; VON WILLEBRAND FACTOR;

ADULT; ALLELE; ARTICLE; BIOAVAILABILITY; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HAPLOTYPE; HEMOLYSIS; HUMAN; INTRON; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; TANDEM REPEAT; VARIABLE NUMBER OF TANDEM REPEAT; VASCULAR DISEASE; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPLICATION; ENZYMOLOGY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; STROKE; VASCULAR ENDOTHELIUM;

ADOLESCENT; ALLELES; ANEMIA, SICKLE CELL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FERRITINS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GENE FREQUENCY; HUMANS; HYDRO-LYASES; INTRONS; MALE; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; STROKE; TANDEM REPEAT SEQUENCES; VON WILLEBRAND FACTOR;

EID: 84921361762     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25234     Document Type: Article

References (50)

1. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008; 2008:177-185.
2. Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293:1653-1662.
3. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: Role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program 2005; 2005:51-57.
4. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-142.
5. Schmidt HH, Walter U. NO at work. Cell 1994; 78:919-925.
6. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 1997; 272:F561-F578.
7. Nadaud S, Bonnardeaux A, Lathrop M, et al. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun 1994; 198:1027-1033.
8. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthase. Cardiovasc Res 2001; 51:429-441.
9. Salimi S, Firoozrai M, Nourmohammadi I, et al. Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with coronary artery disease in Iran. Indian J Med Res 2006; 124:683-688.
10. Elshamaa MF, Sabry S, Badr A, et al. Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with chronic kidney disease. Blood Coagul Fibrinolysis 2011; 22:487-492.
11. Wang Y, Kikuchi S, Suzuki H, et al. Endothelial nitric oxide synthase gene polymorphism in intron 4 affects the progression of renal failure in nondiabetic renal diseases. Nephrol Dial Transplant 1999; 14:2898-2902.
12. Miyamoto Y, Saito Y, Kajiyama N, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32:3-8.
13. Hibi K, Ishigami T, Tamura K, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998; 32:521-526.
14. Wang X, Rinehart TA, Wadl PA, et al. A new electrophoresis technique to separate microsatellite alleles. J Biotechnol 2009; 8:2432-2436.
15. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, et al. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009; 11:324-329.
16. Wethers DL. Sickle cell disease in childhood: Part I. Laboratory diagnosis, pathophysiology and health maintenance. Am Fam Physician 2000; 62:1013-1020.
17. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11-16.
18. van Beers EJ, Schaap MCL, Berkmans RJ, et al. CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009; 94:1513-1519.
19. Darbari DS, Onyekwere O, Nouraie M, et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr 2012; 160:286-290.
20. Pashankar FD, Carbonella J, Bazzy-Asaad A, et al. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 2008; 121:777-782.
21. Morris CR, Kim HY, Trachtenberg F, et al. Thalassemia Clinical Research Network. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: A Thalassemia Clinical Research Network report. Blood 2011; 118:3794-3802.
22. Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082-3089.
23. Tabaei BP, Al-Kassab AS, llag LL, et al. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24:1560-1566.
24. Liu MS, Zang J, Evangelista RA, et al. Double-stranded DNA analysis by capillary electrophoresis with laser-induced fluorescence using thidium bromide as an intercalator. Biotechniques 1995; 18:316-323.
25. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: A novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008; 8:620-632.
26. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21:37-47.
27. Wang XL, Mahaney MC, Sim AS, et al. Genetic contribution of endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 1997; 17:3147-3153.
28. Buraczynska M, Ksiazek P, Zaluska W, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19:2302-2306.
29. Li R, Lyn D, Lapu-Bula R, et al. Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function and blood pressure in African Americans. Am J Hypertens 2004; 17:560-567.
30. Vargas AE, da Silva MA, Silla L, et al. Polymorphisms of chemokine receptors and eNOS in Brazilian patients with sickle cell disease. Tissue Antigens 2005; 66:683-690.
31. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med 2008; 44:1506-1528.
32. Neidlinger NA, Larkin SK, Bhagat A, et al. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem 2006; 281:775-781.
33. Gladwin M, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:22-31.
34. Reiter C, Wang X, Tanus-Santos J, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002; 8:1383-1389.
35. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005; 294:81-90.
36. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: Mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005; 19:881-896.
37. Onyekwere OC, Campbell A, Teshome M, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 2008; 29:309-312.
38. Hebbel RP, Osarogiagbon KD. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004; 11:129-151.
39. Nishank SS, Singh MP, Yadav R, et al. Endothelial nitric oxide synthase gene polymorphism is associated with sickle cell disease patients in India. J Hum Genet 2013; 58:775-779.
40. Sharan K, Surrey S, Ballas S, et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 2004; 124:240-243.
41. Duckworth L, Hsu L, Feng H, et al. Physician-diagnosed asthma and acute chest syndrome: Associations with NOS polymorphisms. Pediatr Pulmonol 2007; 42:332-338.
42. Sullivan KJ, Kissoon N, Duckworth LJ, et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med 2001; 164:2186-2190.
43. Chaar V, Tarer V, Etienne-Julan M, et al. ET-1 and ecNOS gene polymorphisms and susceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica 2006; 91:1277-1278.
44. Falk RJ, Jennette JC. Renal disease. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, (eds). Sickle cell disease: Basic principles and clinical practice. New York: Raven Press; 1994. 673-680.
45. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol 2000; 63:205-211.
46. Voskaridou E, Terpos E, Michail S, et al. Early markers of renal dysfunction in patients with sickle cell/b-thalassemia. Kidney Int 2006; 69:2037-2042.
47. McPherson Yee M, Jabbar SF, Osunkwo I, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol 2011; 6:2628-2633.
48. Ahluwalia TS, Ahuja M, Rai TS, et al. Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Mol Cell Biochem 2008; 314:9-17.
49. Pham PT, Pham PC, Wilkinson AH, et al. Renal abnormalities in sickle cell disease. Kidney Int 2000; 57:1-8.
50. Kato GJ. Novel small molecule therapeutics for sickle cell disease: Nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I. Hematology Am Soc Hematol Educ Program 2008; 186-192.